{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HER2+Positive+Breast+Carcinoma&page=3", "query": { "condition": "Advanced HER2 Positive Breast Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 310, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HER2+Positive+Breast+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+HER2+Positive+Breast+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T20:07:38.669Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00824733", "title": "Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "PF03512676", "type": "DRUG" }, { "name": "Correlative Studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bhuvaneswari Ramaswamy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00824733" }, { "nct_id": "NCT06172127", "title": "PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection", "type": "DRUG" }, { "name": "Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedSIR", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2024-07-22", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172127" }, { "nct_id": "NCT05501886", "title": "Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Alpelisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 701, "start_date": "2022-12-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05501886" }, { "nct_id": "NCT02269670", "title": "Phase II Study of Everolimus Beyond Progression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2014-11-25", "completion_date": "2021-01-25", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269670" }, { "nct_id": "NCT06380751", "title": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Saruparib (AZD5305)", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 788, "start_date": "2024-08-01", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06380751" }, { "nct_id": "NCT04059484", "title": "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-10-22", "completion_date": "2025-01-02", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059484" }, { "nct_id": "NCT02756364", "title": "Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2016-07-28", "completion_date": "2019-11-25", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 30, "location_summary": "Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756364" }, { "nct_id": "NCT02003209", "title": "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-Positive Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Aromatase Inhibition Therapy", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Whole Breast Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 315, "start_date": "2014-02-18", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 731, "location_summary": "Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003209" }, { "nct_id": "NCT01610284", "title": "Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BKM120", "type": "DRUG" }, { "name": "BKM120 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1147, "start_date": "2012-08-07", "completion_date": "2019-04-19", "has_results": true, "last_update_posted_date": "2020-08-25", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 61, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Arcadia", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01610284" }, { "nct_id": "NCT04711252", "title": "A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "AZD9833 placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1371, "start_date": "2021-01-28", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-10T20:07:38.669Z", "location_count": 30, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Harbor City", "state": "California" }, { "city": "Solvang", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711252" } ] }